DocMorris at Global Markets Forum Conference: ai push lifts growth

DocMorris reported H1 2026 revenue growth above 30% and narrowed adjusted EBITDA losses to EUR 11 million from EUR 29 million a year earlier; Rx revenue rose 38.3%, reaching 46% growth in Q2. Management raised full-year 2026 revenue-growth guidance to 30% in local currency, maintained Rx growth guidance of at least 40%, and targets quarterly EBITDA breakeven in H2, while guiding to adjusted EBITDA of negative EUR 10 million to negative EUR 7.5 million for the year. The company cited AI-driven efficiency measures, including replacing more than 100 FTE positions and expected savings above CHF 15 million by end-2027; it said near-term M&A is not a priority and reported refinancing a convertible bond at a 1.5% coupon versus 3% previously.

Analysis

The key underwriting question is whether Rx acquisition is profitable after the co-payment subsidy—not whether customer counts or Rx revenue are growing. The reported gross-margin drag suggests a real trade-off: subsidies can improve conversion and lifetime sales, but the stated 10x five-year sales gap is not a 10x profit or cash-flow gap. Track contribution margin by new Rx cohort and payback period; these are more decision-useful than headline growth.

DOCM’s near-term upside is increasingly execution-dependent after a sharp six-month rerating. TeleClinic and retail media may diversify earnings, but their reported scale remains small relative to the group, so they cannot yet offset a miss in pharmacy economics. The AI savings claim could help the path to breakeven, but savings are forward-looking and execution-sensitive; the article also gives an internally inconsistent timing reference for recurring AI benefits (end-2025 despite a 2026 launch) and describes CapEx as reduced to below CHF30m from about CHF20m. Verify both against filings before underwriting them.

Over 1–3 months, the next results should test whether Rx growth converts to lower cash burn and quarterly breakeven. Over 6–18 months, the upside case depends on German online penetration rising without customer-acquisition subsidies eroding unit economics; regulatory or reimbursement changes could impair that mechanism. A lower-coupon convertible eases carry, but conversion terms and dilution at higher share prices still matter. Competitive pressure from Redcare Pharmacy could force continued incentives. The contrarian risk is treating market underpenetration as guaranteed share capture: incumbent pharmacies, service reliability, and prescription economics—not AI branding—will determine returns.

Key Decisions for Investors

• Avoid chasing DOCM after the rerating. For new exposure, wait for a pullback or the next results, then require evidence that Rx cohort contribution and operating cash flow improve alongside growth.
• If holding DOCM, keep the position sized for execution risk; reassess on any miss to the H2 quarterly-breakeven objective or evidence that co-payment costs are rising faster than customer economics.
• Set a watch item for filings: reconcile the AI-savings timing and CapEx guidance, and review convertible conversion price, dilution and settlement terms before crediting the balance-sheet claims.
• Falsify the constructive thesis if Rx growth decelerates materially, customer acquisition costs or gross-margin pressure worsen, or management withdraws the breakeven path. A credible improvement in cash flow without subsidy expansion would support reconsidering the long.